Cagrilintide 10mg Research Peptide
Cagrilintide is a long-acting synthetic analogue of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells, developed by Novo Nordisk. It acts as an amylin receptor agonist, activating AMY1, AMY2, and AMY3 receptors — heterodimers of the calcitonin receptor with receptor activity-modifying proteins (RAMPs) — to produce satiety signaling, gastric emptying inhibition, and glucagon suppression. Cagrilintide is notable for its role in combination research with semaglutide (the CagriSema combination) which has shown additive weight reduction effects versus either compound alone in Phase 2 trials. This 10mg vial provides research-grade cagrilintide at ≥99% purity, HPLC and MS/MS verified per batch.
Research Background
Amylin receptor agonism produces complementary and non-overlapping mechanisms to GLP-1 receptor agonism, making cagrilintide a valuable combinatorial research tool. Phase 2 trial data for the CagriSema combination (cagrilintide 2.4mg + semaglutide 2.4mg) demonstrated approximately 15.6% mean weight reduction at 32 weeks — substantially exceeding semaglutide alone and positioning amylin/GLP-1 dual agonism as a competitive research frontier alongside GIP/GLP-1 and triple agonist approaches. Phase 3 REDEFINE trials of CagriSema are ongoing as of 2026.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 10mg per vial
- Storage: −20°C, protected from light
- Target: Amylin receptors (AMY1/2/3)
Certificate of Analysis
All cagrilintide vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
